Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 collaboration revenue $11.4 million, up from $4.7 million year over year
- ➤YTD collaboration billings reached approximately $100 million, versus $24 million revenue
- ➤Q3 net loss widened to $38.5 million from $21.5 million
- ➤Pro forma cash reached approximately $455 million after IPO and AbbVie payments
- ➤IAM1363 showed 36% systemic and 41% intracranial response rates in Phase 1/2
- ➤Takeda milestone triggered a $1.0 million payment in Q3
Expert Statements
Tom Miller, Co-Founder and CEO of Iambic
“Iambic’s mission is to make better technology for better medicines, and we believe that the past several months showed that at work across every part of our business”
Tom Miller, Co-Founder and CEO of Iambic
“At ESMO, our updated clinical data showed the intracranial activity and tolerability for IAM1363, and we are preparing to start a registrational trial in 2027, subject to regulatory approval.”
Tom Miller, Co-Founder and CEO of Iambic
“We submitted the IND and have received a Safe-to-Proceed Letter for a Phase 1/2 trial for IAM217, our second wholly owned and platform-discovered candidate, with an anticipated IND submission for IAM-C1, our CDK2/4 inhibitor, close behind.”
Tom Miller, Co-Founder and CEO of Iambic
“We launched Enchant v3, a huge advance in the core AI technology that underpins our molecular superintelligence platform, and AbbVie and Bayer each chose to bring our platform to bear on their own discovery work through new Iambic partnerships.”
Tom Miller, Co-Founder and CEO of Iambic
“Our IPO gives us the resources to advance our pipeline through major inflection points and to keep scaling the platform behind it.”
* Launched Enchant® v3, a 41-billion-parameter transformer model for drug discovery and development, to drive decisions across our internal and partnership activities * Signed AI discovery collaborations with Bayer and AbbVie; eight total partnerships signed since 2024 * Achieved a program milestone in Takeda collaboration, triggering a $1.0 million payment; AI-driven drug discovery collaboration was announced only nine months ago in February 2026 * Presented updated IAM1363 (HER2) data from ongoing Phase 1/2 study at ESMO 2026: 36% systemic and 41% intracranial best overall response rates in heavily pretreated patients; registrational trial planned for 2027, subject to regulatory approval * Submitted IND and received a Safe-to-Proceed Letter from the FDA for the IAM217 (KIF18A) Phase 1/2 trial; IND submission for IAM-C1 (CDK2/4) is on track for Q4 2026 * Meaningful revenue generation: YTD (through Q3 2026), collaboration revenue was approximately $24 million, where billings from collaborations were approximately $100 million; for the same period, Iambic’s total operating expenses were approximately $108 million and costs related to compute were less than $10 million * Strong cash position: As of September 30, 2026, the cash and cash equivalents position was approximately $252 million, where the pro-forma cash and cash equivalents position was approximately $455 million and includes net proceeds of approximately $156 million from our IPO and AbbVie upfront payments received in October 2026 SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today provided business updates and financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.
